Nature Communications (Feb 2022)

The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhbdf2 in mouse hepatocytes

  • Minxuan Xu,
  • Jun Tan,
  • Wei Dong,
  • Benkui Zou,
  • Xuepeng Teng,
  • Liancai Zhu,
  • Chenxu Ge,
  • Xianling Dai,
  • Qin Kuang,
  • Shaoyu Zhong,
  • Lili Lai,
  • Chao Yi,
  • Tingting Tang,
  • Junjie Zhao,
  • Longyan Wang,
  • Jin Liu,
  • Hao Wei,
  • Yan Sun,
  • Qiufeng Yang,
  • Qiang Li,
  • Deshuai Lou,
  • Linfeng Hu,
  • Xi Liu,
  • Gang Kuang,
  • Jing Luo,
  • Mingxin Xiong,
  • Jing Feng,
  • Chufeng Zhang,
  • Bochu Wang

DOI
https://doi.org/10.1038/s41467-022-28641-w
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 20

Abstract

Read online

Nonalcoholic steatohepatitis (NASH) is a chronic liver disease with complex disease mechanisms. Here the authors report that the E3 ubiquitin-protein ligase Trim31 mitigates development of NASH via inhibition of rhomboid 5 homolog 2 (Rhbdf2) in mice.